- Conditions
- Schizophrenia
- Interventions
- repetitive transcranial magnetic stimulation (active), repetitive transcranial magnetic stimulation (sham)
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 1,652
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Psychosis
- Interventions
- Family Focused Treatment, Enhanced Care
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Diego, California • New Haven, Connecticut + 4 more
- Conditions
- Schizophrenia
- Interventions
- N-Acetylcysteine, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Autism, Aggression, Bipolar Disorder, Psychotic Disorders
- Interventions
- Family Navigator consultation
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Cognitive Behavior Treatment
- Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Claremont, New Hampshire
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- West Los Angeles, California
- Conditions
- First Episode Psychosis
- Interventions
- Stakeholder feedback, Data infrastructure
- Other
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- Lurasidone 40 mg, Lurasidone 80 mg, Placebo 40 or 80 mg
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 36
- States / cities
- Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Interventions
- Varenicline, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
- Conditions
- Velo-cardio-facial Syndrome, Psychosis
- Interventions
- Metyrosine, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Schizophrenia, Schizoaffective Disorder, Control Subjects
- Interventions
- Positive Emotion Upregulation
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Psychotic Disorders, Mood Disorders, Anxiety Disorders
- Interventions
- Resilience Training (RT), Life Skills Training (LST)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- TAK-063 20 mg, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
- Conditions
- Bipolar Disorder, Schizophrenia
- Interventions
- Divalproex-extended release (DVP-ER), Lithium, Quetiapine
- Drug
- Lead sponsor
- Palo Alto Veterans Institute for Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Schizophrenia, Cigarette Smoking
- Interventions
- Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging
- Drug · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- First Episode Psychosis, Schizophrenia
- Interventions
- Social Network Meetings
- Behavioral
- Lead sponsor
- Lisa Dixon
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Yonkers, New York
- Conditions
- Schizophrenia, Alcohol Use Disorder
- Interventions
- Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 58
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
- Conditions
- Schizophrenia
- Interventions
- AZD0328, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Garden Grove, California • Glendale, California
- Conditions
- Major Depression With Psychotic Features
- Interventions
- quetiapine
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Schizophrenia
- Interventions
- Clozapine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Catonsville, Maryland
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
- Drug
- Lead sponsor
- Matt Byerly
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Schizophrenia, Schizoaffective Disorder
- Interventions
- RP5063, placebo, aripiprazole
- Drug
- Lead sponsor
- Reviva Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania